This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary disease received approval from the Food and Drug Administration.
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday.
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to schizophrenia treatment in decades,
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.
Breakthrough in Schizophrenia Treatment: FDA Approves Cobenfy
New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects 1.8 percent of the U.
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental illness in more than 30 years.
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to target cholinergic receptors rather than dopamine receptors,
The FDA Is Launching New Traceability Rules for Added Food Safety — and Everyone Is Confused
On January 20, 2026, the Food and Drug Administration's (FDA) new traceability rules — dubbed the Food Traceability Final ...
STAT1d
The FDA is ‘making sandwiches,’ ‘breakfast salad’ in DC, and what keeps us from choking on food
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...
NBC New York3d
FDA issues recall notices over 2 brands of pet food due to salmonella and listeria risk
Amid an ongoing pet food recall, the U.S. Food and Drug Administration (FDA) is urging pet owners not to give their ...
What to Know About the FDA’s New Dog Food Recalls
Check your pup's food right away to see if it’s included in these dog food recalls. Your dog's health—and yours—may depend on ...
Business Wire1d
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
FDA issues recall notices for two brands of pet food over salmonella and listeria contamination
Pet owners are advised to throw away the at-risk products safely, so pets and children can't access and ingest them ...